Business Context and Reporting Period
This Form 8-K is filed by Landec Corporation (not Lifecore Biomedical, Inc., which is a subsidiary) on September 23, 2016. The filing reports on two primary events: the announcement of consolidated financial results for the first quarter of fiscal year 2017 ended August 28, 2016, and the execution of a new credit facility on September 23, 2016.
Key Financial Metrics and Debt Structure
The filing details a significant refinancing of the company's debt structure rather than providing specific revenue or profit figures in the text body (these are referenced in an attached press release).
- New Credit Facility: A $100,000,000 revolving line of credit (Revolver) and a $50,000,000 term loan.
- Lenders: JPMorgan Chase Bank, N.A. (administrative agent), BMO Harris Bank N.A., and City National Bank.
- Maturity: Both facilities mature on September 23, 2021 (5 years).
- Term Loan Repayment: Quarterly principal payments of $1,250,000 commencing November 2016, with the remainder due at maturity.
- Interest Rate: Variable based on the "Total Leverage Ratio," calculated as Prime + 0.25% to 1.25% or Eurodollar + 1.25% to 2.25%.
- Debt Repayment: Proceeds were used to repay approximately $50,069,000 in existing debt owed to Wells Fargo Bank, N.A. and Bank of America, N.A.
- Security: The debt is secured by substantially all personal property assets of the company and its subsidiaries, with an exception for Apio, Inc.'s equity interest in Windset Holdings 2010 Ltd.
Material Changes Versus Prior Period
The primary material change is the complete refinancing of existing term loan facilities. The company replaced prior obligations with a new $150,000,000 total capacity facility (Revolver + Term Loan), extending the maturity date to 2021 and introducing an "accordion" feature allowing for up to an additional $75,000,000 in commitments.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release (Exhibit 99.1) for Q1 FY2017 results but does not contain specific guidance or outlook text within the 8-K body.
Risks and Contingencies:
- Covenants: The Credit Agreement includes customary events of default that could trigger acceleration of obligations or increased interest rates.
- Collateral: The company has pledged substantially all personal property assets as security.
- Legal Status: The financial results and press release information are furnished and not deemed "filed" under Section 18 of the Exchange Act, limiting their incorporation by reference in other filings.
Investor Verification Checklist
- Verify the specific Q1 FY2017 revenue, net income, and cash flow figures in the attached Press Release (Exhibit 99.1), as they are not detailed in this text.
- Confirm the current "Total Leverage Ratio" to determine the applicable interest rate spread on the new debt.
- Review the full Credit Agreement (Exhibit 10.1) for specific financial covenants and definitions of "Total Leverage Ratio."
- Assess the impact of the new debt structure on future cash flow requirements due to the quarterly principal payments starting November 2016.